πŸ‡ΊπŸ‡Έ

US SEC Filing Intelligence

Daily AI-powered analysis of SEC EDGAR filings, FDA approvals, and US regulatory disclosures. Investment signals, risk flags, and sector themes for US markets.

Β·daily

US Earnings Financial Results SEC Filings β€” March 09, 2026

Across 50 US SEC filings for FY2025 and early 2026, mixed sentiment prevails in 40+ cases, reflecting revenue volatility amid cost controls narrowing losses in biotechs (avg net loss improvement ~25% YoY in 15/20 biotechs) but widening in others due to impairments (e.g., $616M crypto losses at SharpLink). Revenue trends show stark divergence: explosive growth in select biotechs/pharma (Zevra +350% YoY, Cumberland +17.6%) contrasted by declines in healthcare staffing (-21.6% Cross Country), diagnostics (-38% OraSure), and manufacturing (-12% 3D Systems). Financials exhibit resilience with NIM expansion (Tri-County +44bps, Heritage +31bps) and ROE gains (Tri-County +1.64pp), while SPACs (8 filings) uniformly report trust interest-driven net income (avg +$4M YoY). Impairments aggregate >$2B (e.g., NET Power $1.5B, Repay $242M), signaling overvalued assets, but cash raises bolster biotechs (e.g., enGene +$151M). Capital allocation leans conservative: dividend cuts (Tiptree -51%, Caseys up 14%) and buybacks absent; M&A limited. Portfolio implication: Biotech turnarounds and regional banks offer alpha, avoid impairment-heavy cyclicals amid 2026 policy risks (EVgo OBBBA).

50 high priority50 total filings
Β·daily

US Earnings Financial Results SEC Filings β€” March 06, 2026

Across 102 SEC filings for FY2025/Q1 FY2026 financial results, mixed sentiment dominates (95/102 filings), reflecting resilient revenue growth in tech (e.g., Chime +31%, Guidewire +25%), banking (avg loan growth 10-20%), and energy (Granite Ridge +18%) but offset by widening losses from impairments, higher expenses, and margin compression in REITs/BDCs (avg NOI +10-20% but net losses up 10-50%). Period-over-period trends show YoY revenue growth in 60% of filers (median +12%) but operating margins mixed with compression in 40% (avg -100bps), driven by capex/debt rises; cash from ops improved in 55% (median +20%) amid cost controls. Banking outliers shine with NIM expansions (Republic Bancorp +20bps to 5.05%), while REITs face NOI declines (Ares same-store -2.1%); BDCs/SPACs highlight portfolio expansions but NAV drops. Capital allocation favors dividends/buybacks stability (e.g., Camden National flat $0.42/share), but debt rises signal leverage risks. Forward catalysts cluster around Q1 2026 earnings/AGMs (Apr-May), M&A closes (e.g., Hometown Jan 2026), and SPAC deadlines (May-Jun 2026). Implications: Tactical longs in high-ROE banks/tech, shorts on impaired REITs; portfolio tilt to NIM-expanders amid rate uncertainty.

102 high priority102 total filings
Β·daily

US Earnings Financial Results SEC Filings β€” March 05, 2026

Across 109 US SEC filings for Q4 FY2025/early FY2026 financial results, overarching themes include mixed revenue performance with ~55% of companies (60/109) reporting YoY growth averaging +25% (outliers like Liquidia +1031%, Hippo +26%), offset by declines in ~30% averaging -10% (e.g., Olaplex flat, Rayonier -10%), driven by sector-specific pressures in industrials/energy and boosts in biotech/fintech from collaborations/new products. Profitability improved in 65% with average net loss narrowing ~35% YoY via cost controls/impairment reversals, though 25% swung to losses amid impairments (StubHub $1.91B loss). Margin trends show compression averaging -80bps in tech/manufacturing (7/12 firms, e.g., CPI Card -430bps), expansion +150bps in financials (NIM +25bps avg across 12 banks). Capital allocation favors dividends/buybacks in 18 firms (e.g., Toro repurchases), with debt surges in 20% post-refinancing (Ferrellgas +78%). Biotech/pharma (35 filings) dominate with collab revenue +48% avg but high R&D burns; positive sentiment in 5% (Okta, CorMedix). Portfolio implication: Bullish on profitable growers (TaskUs +123% NI), cautious on high-burn biotechs; alpha in NIM-expanders amid rate cuts.

109 high priority109 total filings
Β·daily

US Earnings Financial Results SEC Filings β€” March 04, 2026

Across 74 SEC filings primarily 10-Ks for FY2025, US companies showed mixed financial results with 42/74 reporting revenue growth (avg +12% YoY where specified), but 51/74 had net losses or widened losses, driven by impairments (e.g., Grocery Outlet $149M goodwill, Oil States $100M), margin compression (avg -150bps in 28 cos), and rising SG&A (up avg 15% in 35 cos). Energy firms like Gran Tierra (-30% prices, $136M impairment) and Ring Energy (negative gas prices) faced commodity headwinds, while finance (e.g., First Financial NII +25.6%, Unity ROA 2.17%) and select biotech (Keros revenue +6772%, SCYNEXIS +450%) outperformed. Capital allocation leaned defensive with buybacks (e.g., Kontoor $25M, Daktronics $22.8M) and dividends steady, but debt reductions (Oil States to $1.7M) signal deleveraging. Portfolio trends highlight retail weakness (comp sales flat/-5% avg in 5 cos) vs. resilience in niche growth like Red Violet (+20% rev). Implications: Favor financials/biotech turnarounds, avoid energy/retail amid cost pressures; watch Q1 2026 earnings for guidance updates.

74 high priority74 total filings